123 related articles for article (PubMed ID: 6751436)
1. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).
Kempin S; Lee BJ; Thaler HT; Koziner B; Hecht S; Gee T; Arlin Z; Little C; Straus D; Reich L; Phillips E; Al-Mondhiry H; Dowling M; Mayer K; Clarkson B
Blood; 1982 Nov; 60(5):1110-21. PubMed ID: 6751436
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV).
Case DC; Porensky RS; Fanning JP
Oncology; 1985; 42(6):350-3. PubMed ID: 4069549
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
4. Diffuse well-differentiated lymphocytic lymphoma: chemotherapy with BCNU, cyclophosphamide, vincristine, melphalan and prednisone.
Case DC; Boyd M; Hayes DM; Dorsk BM
Oncology; 1988; 45(6):417-20. PubMed ID: 3054672
[TBL] [Abstract][Full Text] [Related]
5. A new combination chemotherapy for advanced chronic lymphocytic leukemia (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone protocol).
Ferrara F; Del Vecchio L; Mele G; Rametta V; Ronconi F; Montuori R
Cancer; 1989 Aug; 64(4):789-92. PubMed ID: 2743271
[TBL] [Abstract][Full Text] [Related]
6. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
[No Abstract] [Full Text] [Related]
8. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy (M-2) protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for Waldenström macroglobulinemia: preliminary report.
Case DC
Blood; 1982 May; 59(5):934-7. PubMed ID: 6803856
[TBL] [Abstract][Full Text] [Related]
10. Comparison of M-2 protocol with COP in patients with nodular lymphoma.
Case DC
Oncology; 1984; 41(3):159-63. PubMed ID: 6547220
[TBL] [Abstract][Full Text] [Related]
11. Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
Cornwell GG; Pajak TF; Kochwa S; McIntyre OR; Glowienka LP; Brunner K; Rafla S; Silver RT; Cooper MR; Henderson E; Kyle RA; Haurani FI; Cuttner J
Cancer; 1982 Nov; 50(9):1669-75. PubMed ID: 7116299
[TBL] [Abstract][Full Text] [Related]
12. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.
Montserrat E; Alcalá A; Parody R; Domingo A; García-Conde J; Bueno J; Ferrán C; Sanz MA; Giralt M; Rubio D
Cancer; 1985 Nov; 56(10):2369-75. PubMed ID: 3899346
[TBL] [Abstract][Full Text] [Related]
14. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
[TBL] [Abstract][Full Text] [Related]
15. Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia.
Sackmann Muriel F; Svarch E; Pavlovsky S; Bustelo P; Giuntoli J; Vergara B; Garay G; Eppinger-Helft M; Kvicala R; Dibar E
Cancer Treat Rep; 1984 Apr; 68(4):581-6. PubMed ID: 6370428
[TBL] [Abstract][Full Text] [Related]
16. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
[TBL] [Abstract][Full Text] [Related]
17. Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study).
Pullen DJ; Sullivan MP; Falletta JM; Boyett JM; Humphrey GB; Starling KA; Land VJ; Dyment PG; Vats T; Duncan MH
Blood; 1982 Nov; 60(5):1159-68. PubMed ID: 6982085
[TBL] [Abstract][Full Text] [Related]
18. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
19. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
Bladé J; San Miguel JF; Fontanillas M; Esteve J; Maldonado J; Alcalá A; Brunet S; García-Conde J; Besalduch J; Moro MJ; Fernández-Calvo J; Conde E; Font L; Gardella S; Carnero M; Carbonell F; Martí JM; Hernández-Martín J; Ortega F; Besses C; Ribera JM; Trujillo J; Escudero ML; Rozman C; Estapé J; Montserrat E
Hematol J; 2001; 2(4):272-8. PubMed ID: 11920260
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]